The present disclosure provides methods and systems for ghost cytometry (GC), which may be used to produce an image of an object without using a spatially resolving detector. This may be used to perform image-free ultrafast fluorescence “imaging” cytometry, based on, for example, a single pixel detector. Spatial information obtained from the motion of cells relative to a patterned optical structure may be compressively converted into signals that arrive sequentially at a single pixel detector. Combinatorial use of the temporal waveform with the intensity distribution of the random or pseudo-random pattern may permit computational reconstruction of cell morphology. Machine learning methods may be applied directly to the compressed waveforms without image reconstruction to enable efficient image-free morphology-based cytometry. Image-free GC may achieve accurate and high throughput cell classification as well as selective sorting based on cell morphology without a specific biomarker, which have been challenging using conventional flow cytometers.
A liquid crystal element is provided that can inhibit occurrence of voltage drop between one end and the other end of each electrode. A liquid crystal element (100) includes a liquid crystal layer LQ, a plurality of first arcuate electrodes (1), and a plurality of second arcuate electrodes (2). The first arcuate electrodes (1) are disposed concentrically about an optical axis (AX) of the liquid crystal element (100) and applies first voltage (Vi) to the liquid crystal layer (LQ). The second arcuate electrodes (2) are disposed concentrically about the optical axis (AX) and applies second voltage (V2) to the liquid crystal layer (LQ).
G02F 1/29 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de la position ou de la direction des rayons lumineux, c. à d. déflexion
G02B 3/14 - Lentilles remplies d'un fluide ou à l'intérieur desquelles le vide a été fait à distance focale variable
3.
DEVICE, IONIC CURRENT MEASUREMENT APPARATUS, ZETA POTENTIAL MEASUREMENT APPARATUS, IONIC CURRENT MEASUREMENT METHOD, AND ZETA POTENTIAL MEASUREMENT METHOD
An object is to provide a device that can measure a moving time (velocity) of a single particle with high accuracy, and an ion current measuring apparatus and a zeta potential measuring apparatus with the device, and an ion current measuring method and a zeta potential measuring method. The object can be achieved by a device used for measurement of ion current, the device including: a substrate; and a channel formed in the substrate. The channel includes a sample liquid supply channel, a sample collection channel, and constricted channel formed between the sample liquid supply channel and the sample collection channel. The constricted channel includes three or more constricted parts each formed with a protrusion part, the three or more constricted parts are formed substantially straight in a direction from the sample liquid supply channel to the sample collection channel, and when the width of each of the constricted parts is defined as 1, the spacing between adjacent constricted parts is 0.5 to 3.
The present invention relates to an evaluation device 4 for evaluating the severity of pneumonia in a target patient, comprising: an acquisition unit 42 for acquiring a respiratory waveform of the target patient; a calculation unit 43 for calculating a value of an index indicating instability of a respiratory cycle or a respiratory frequency from the respiratory waveform; and an evaluation unit 44 for evaluating the severity based on the calculated value.
National Institutes of Biomedical Innovation, Health and Nutrition (Japon)
Kagami Inc. (Japon)
Inventeur(s)
Isaka, Yoshitaka
Kimura, Tomonori
Kimura, Shihoko
Mita, Masashi
Abrégé
Provided herein is a method for providing information about virus infection and/or virus infection disease in a subject, comprising: making a determination on the detection and/or stage classification of virus infection and/or virus infection disease in the subject using an indicator associated with a D-amino acid in the subject; and providing information about virus infection and/or virus infection disease in the subject based on the results of the determination.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
6.
BORONIC ACID COMPOUND AND METHOD FOR PRODUCING SAME
The invention provides a method for producing radiolabeled tyrosine derivatives with good purity and stability, by a safe method suitable for industrial production of pharmaceuticals. The invention relates to a method for producing Compound (5) and Radiolabeled Compound (6) as follows:
The invention provides a method for producing radiolabeled tyrosine derivatives with good purity and stability, by a safe method suitable for industrial production of pharmaceuticals. The invention relates to a method for producing Compound (5) and Radiolabeled Compound (6) as follows:
The invention provides a method for producing radiolabeled tyrosine derivatives with good purity and stability, by a safe method suitable for industrial production of pharmaceuticals. The invention relates to a method for producing Compound (5) and Radiolabeled Compound (6) as follows:
wherein each symbol is as defined in the description.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07C 227/16 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions n'impliquant pas les groupes amino ou carboxyle
C07F 13/00 - Composés contenant des éléments des groupes 7 ou 17 de la classification périodique
7.
METHOD FOR PRODUCING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN THE SAME
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
Kyoto Prefectural Public University Corporation (Japon)
Inventeur(s)
Kitano, Shiro
Matsusaki, Michiya
Louis, Fiona
Sowa, Yoshihiro
Abrégé
A method for producing a three-dimensional tissue construct comprising mature adipocytes, comprising incubating cells comprising at least fat-derived stein cells in the presence of one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
A permanent magnet-type rotary electric machine includes a stator, a first rotor, and a second rotor. The stator includes a stator core, a plurality of stator teeth, a plurality of stator slots, a plurality of stator magnets, and a stator coil. The first rotor is disposed inside the stator core relative to the plurality of stator magnets. The second rotor is disposed inside the stator core relative to a plurality of first pole pieces. The second rotor includes a plurality of second pole pieces. A proportion of the number of the plurality of stator slots to the number of poles of the plurality of second pole pieces of the second rotor is greater than 1.25 and less than 1.5, or greater than 1.5 and less than 3.0.
A spectrometry apparatus (1) according to an embodiment includes a detection object lens that signal light from a sample S enters, a slit (41) through which the signal light passes, a wavelength dispersive element that disperses the signal light having passed the slit (41) in accordance with a wavelength, an optical detector (50) that detects the signal light that has been subjected to wavelength dispersion in the wavelength dispersive element, scanning means for scanning a detection region of the optical detector (50) in the sample, a processing unit (51) that generates a spectral image, based on a detection signal of the optical detector (50), and an illumination optical system (10) that illuminates the sample from a side of the detection object lens.
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Fujita, Katsumasa
Nishida, Kentaro
Sato, Hikaru
Tanaka, Hideo
Harada, Yoshinori
Abrégé
A diagnostic optical microscope according to the present embodiment includes at least one laser light source (11) configured to generate laser light for illuminating a sample (40) containing a light absorbing material, a lens configured to focus the laser light to be focused on the sample (40), scanning means for changing a focusing position of the laser light on the sample (40), and a light detector (31) configured to detect laser light transmitted through the sample (40) as signal light. A laser light intensity is changed to obtain a nonlinear region in which the laser light intensity and a signal light intensity have a nonlinear relation due to occurrence of saturation of absorption in the light absorbing material when the laser light intensity is maximized. An image is generated based on a nonlinear component of the signal light based on the saturation of absorption in the light absorbing material.
G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
G01N 33/483 - Analyse physique de matériau biologique
Provided is a magnetic strain wave gear device that makes it possible to achieve both improvement of the efficiency of assembly work and suppression of decrease in energy conversion efficiency. A magnetic strain wave gear device includes: a stator having a stator core, a stator winding, and a stator magnet; a first rotor; and a second rotor. The second rotor includes a second rotor core provided with a plurality of rotor magnet insertion holes and a plurality of rotor magnets inserted into the plurality of respective rotor magnet insertion holes. The first rotor includes a cylindrical first rotor core and a first rotor end plate. The first rotor end plate has a rotor magnet passage hole through which the rotor magnets can be inserted into the rotor insertion holes from outside in a direction of a rotation shaft.
A wall thickness estimation method includes: obtaining behavioral information based on a video in which an organ wall or a blood vessel wall is captured using four-dimensional angiography, the behavioral information being numerical information about changes over time in a position of each of a plurality of predetermined points in the organ wall or the blood vessel wall; generating, based on the behavioral information obtained in the obtaining, estimation information that visualizes a strain of each of the plurality of predetermined points for estimating a thickness of the organ wall or a thickness of the blood vessel wall; and outputting the estimation information generated in the generating.
An information processing apparatus determines a combination of a first data qubit and a second data qubit that further reduces the energy represented by an energy equation. The energy equation includes first to third energy terms. The first energy term is used to identify the first data qubit on which a Z error has occurred. The second energy term is used to identify the second data qubit on which an X error has occurred. The third energy term reduces the energy as the number of data qubits each being a third data qubit on which both a Z error and an X error have simultaneously occurred increases. The information processing apparatus determines that a Y error has occurred on the third data qubit.
The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.
An exercise support apparatus includes an information processing unit that supports a setting of a next exercise menu for improvement to a targeted body, based on prior body motion information on a subject detected by a motion sensor. The information processing unit includes an image display processing unit that outputs distribution information on an amount of activity and a number of steps of at least one category obtained by classifying activity intensity that has been obtained from a target people group in advance, for each of the selected category, stored in a storage unit, and selected in advance, to a display unit, an activity amount processing unit that calculates the amount of activity and the number of steps for a same category as a selected category, based on body motion information on the subject, and that stores a calculation result in a measurement data storage unit, and an image display processing unit that outputs the amount of activity and the number of steps that have been calculated by the activity amount processing unit, to the display unit.
An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression.
An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression.
A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.
An objection is to provide a method for characterizing a molecule delivery particle, the method comprising determining a molar concentration thereof.
An objection is to provide a method for characterizing a molecule delivery particle, the method comprising determining a molar concentration thereof.
The method for characterizing a molecule delivery particle, the method comprising subjecting a molecule delivery particle comprising a first particle and a second particle to particle separation with optical measurement to determine an increment in refractive index of each of the first particle and the second particle; and determining a molar concentration of each of the first particle and the second particle based on the increment in refractive index, a molecular weight, and a specific refractive index increment of each of the first particle and the second particle.
G01N 21/33 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière ultraviolette
G16B 40/10 - Traitement du signal, p.ex. de spectrométrie de masse ou de réaction en chaîne par polymérase
20.
SEMICONDUCTOR NANOPARTICLE, METHOD FOR MANUFACTURING SAME, AND LIGHT EMITTING DEVICE
National University Corporation Tokai National Higher Education and Research System (Japon)
OSAKA UNIVERSITY (Japon)
NICHIA CORPORATION (Japon)
Inventeur(s)
Torimoto, Tsukasa
Kameyama, Tatsuya
Mori, Yuki
Yamauchi, Hiroki
Kuwabata, Susumu
Uematsu, Taro
Oyamatsu, Daisuke
Abrégé
Provided is a method for manufacturing a semiconductor nanoparticle, the method includes performing a heat treatment of a first mixture containing a silver (Ag) salt, an alkali metal salt, a salt containing at least one of indium (In) and gallium (Ga), a sulfur source, and an organic solvent. A ratio of the number of atoms of an alkali metal to the total number of atoms of Ag and the alkali metal in the first mixture is greater than 0 and less than 1.
H01L 33/06 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure à effet quantique ou un superréseau, p.ex. jonction tunnel au sein de la région électroluminescente, p.ex. structure de confinement quantique ou barrière tunnel
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p.ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
B82Y 40/00 - Fabrication ou traitement des nanostructures
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
21.
External Preparation for Treating Epilepsy or Autism Spectrum Disorder
[Object] It is an object to provide a highly safe and easy-to-administer pharmaceutical preparation for treating epilepsy, pharmaceutical preparation for treating an autism spectrum disorder, and/or pharmaceutical preparation for treating an anxiety disorder. [Solving Means] A topical preparation containing as an active ingredient at least one selected from the group consisting of sirolimus and a sirolimus derivative is a pharmaceutical preparation that is easy to administer, and is highly safe as a therapeutic agent for epilepsy, an autism spectrum disorder, and/or an anxiety disorder. Suitable examples of the active ingredient include sirolimus, everolimus, temsirolimus, ridaforolimus, and zotarolimus.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p.ex. phosphate de pyridoxal
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
An optical module according to the present embodiment includes: a first lens array unit in which a plurality of first lenses configured to collect irradiating light are arranged; a second lens array unit which includes a plurality of second lenses and on which signal light from the first lenses is incident; and a plurality of beam splitters configured to reflect irradiating light to the first lenses and to transmit the signal light from the first lenses, wherein reflectance of the beam splitter on a nearest side in a travel direction of the irradiating light is set lowest and the more toward a far side in the travel direction, the higher the reflectance of the beam splitters.
G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
The present disclosure includes a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising a blister-derived cell of a patient with dystrophic epidermolysis bullosa that is genetically modified to produce type VII collagen.
The present inventors revealed the following for the first time in the world:
1) a large amount of bone marrow-derived cells are mobilized to grafted skin;
2) the mobilized bone marrow-derived cells are differentiated into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in the grafted skin, and the mobilized bone marrow-derived cells include bone marrow-derived mesenchymal stem cells;
3) the factors which mobilize bone marrow-derived mesenchymal stem cells from peripheral blood to the grafted skin are HMGB1, HMGB2, and HMGB3 released from the necrosed tissue of recipient skin;
4) purified HMGB1, HMGB2, and HMGB3 promote the migration of mesenchymal stem cells isolated and cultured from bone marrow;
5) activators containing HMGB1 which allows the migration of bone marrow mesenchymal stem cells can be conveniently purified from several organ extracts including skin, brain, and heart;
6) activators which allow the migration of bone marrow mesenchymal stem cells can be conveniently extracted from cultured cells; and
7) a heparin-column purified fraction of skin extract mobilizes a large amount of bone marrow-derived cells in case of brain injury.
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
25.
DISEASE OUTBREAK FORECASTING APPARATUS, AND METHOD THEREOF AND STORAGE MEDIUM
An apparatus (1) includes an exercise sensor (31) that continuously detects a movement of an exerciser accompanied by intermittent exercise, and a heart rate meter (32) that continuously measures a heart rate of the exerciser, and further includes an activity detection unit (12), a heart rate monitoring unit (13), an activity monitoring unit (14), and a notification processing unit (15). The activity detection unit (12) detects, from the movement of the exerciser, an activity intensity, a high activity intensity period, and a low activity intensity period. The heart rate monitoring unit (13) detects a declining trend in the heart rate of the exerciser, in the low activity intensity period each time, and monitors whether or not the declining trend of this time is low as compared with a predetermined reference. The activity monitoring unit (14), in a case in which the monitoring by the heart rate monitoring unit is affirmed, monitors whether or not the activity intensity to be detected in the high activity intensity period of a next time is low as compared with activity intensities detected in high activity intensity periods up to a previous time. The notification processing unit (15), in a case in which the monitoring by the activity monitoring unit is affirmed, forecasts an outbreak of disease. With this configuration, the outbreak of disease in an exerciser during an exercise is forecasted with higher accuracy.
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p.ex. de la grippe
A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire
A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
26.
CATHETER SIMULATOR AND HEART MODEL FOR CATHETER SIMULATOR
A heart model includes a main body formed from an elastic material and including a left atrium and a left ventricle, with a mitral valve installed at a boundary portion between the left atrium and the left ventricle; and a vena cava provided in the main body, wherein the mitral valve includes an anterior leaflet and a posterior leaflet, both the leaflets extending to the left ventricle side and capable of opening and closing, and the anterior leaflet and the posterior leaflet are each provided on a tip side with a plurality of string-shaped members extending into the left ventricle.
An object of the present invention is to provide a novel method for producing a ketone derivative, and more specifically, a method for producing a ketone derivative (I) represented by formula (I), including mixing a thioester derivative (II) represented by formula (II), a Grignard reagent (III) represented by formula (III) and a copper salt to form a ketone derivative (I).
C07D 333/22 - Radicaux substitués par des hétéro-atomes liés par une liaison double ou par deux hétéro-atomes, autres que des halogènes, liés au même atome de carbone par des liaisons simples
C07C 45/51 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par pyrolyse, réarrangement ou décomposition
C07C 45/54 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés par pyrolyse, réarrangement ou décomposition de composés contenant des atomes d'oxygène liés par des liaisons doubles, p.ex. d'esters
C07C 67/317 - Préparation d'esters d'acides carboxyliques par modification de la partie acide de l'ester sans introduction d'un groupe ester par hydrogénolyse de groupes fonctionnels
C07C 253/30 - Préparation de nitriles d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes cyano
28.
CATHETER SIMULATOR AND CEREBRAL BLOOD VESSEL MODEL
A catheter simulator includes a container capable of accommodating a liquid in an accommodation part surrounded by side walls and a bottom part; a cerebral blood vessel model held in the container in a state of accommodating a liquid; a pump connected to the container and circulating the liquid inside the cerebral blood vessel model held therein; and a holder provided on the side walls of the container and the cerebral blood vessel model and holding the cerebral blood vessel model in a state of having the container filled with the liquid, wherein the holder includes a first holding part holding an end of an ascending aorta of the cerebral blood vessel model, and a second holding part holding an end of a descending aorta of the cerebral blood vessel model.
An evaluation method is performed by an arithmetic circuit and includes obtainment processing (S1), evaluation processing (S2), and presentation processing (S3). The obtainment processing (S1) obtains: image information on a sectional image representing an interested section of an organism including a target section of a testis of the organism generated by use of magnetic resonance of hydrogen atoms; and concentration information on a creatine concentration in the interested section measured by use of magnetic resonance based on chemical exchange saturation transfer. The evaluation processing (S2) generates an evaluation image representing a distribution of evaluation results of a testicular function in the target section based on the concentration information. The presentation processing (S3) presents the sectional image and the evaluation image.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G01R 33/485 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p.ex. spectroscopie in vivo basés sur l'information de déplacement chimique
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A biosensor is a field-effect transistor-based biosensor including an insulating substrate, and a measurement sensor and a reference sensor on the insulating substrate. A probe molecule is in the measurement sensor. The probe molecule has a first basic moiety in the measurement sensor, and a recognition moiety with a first end bound to the first basic moiety and a second end defining a distal end of the probe molecule. A second basic moiety is in the reference sensor and has a same structure as that of the first basic moiety of the probe molecule in the measurement sensor. The recognition moiety of the probe molecule in the measurement sensor is absent at the distal end of the second basic moiety.
The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
32.
CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICS
The present invention provides a liposome preparation containing a population of liposomes containing a CD1d ligand compound, wherein the average particle size of the population of liposomes is 90 to 110 nm and the polydispersity index of particle size distribution is 0.2 or less. and the polydispersity index of the particle size distribution is 0.2 or less. The present invention also provides the use of the liposome preparation in the prevention or treatment of graft-versus-host disease and organ transplant rejection.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c. à d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p.ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A heart valve abnormality detection device includes a heart sound data acquisition portion 21 configured to acquire heart sound data corresponding to heart sounds, a first processing portion configured to set, based on the heart sound data, a section between a first heart sound and a second heart sound of the heart sounds as a target range and acquire a peak frequency that is a peak value of a frequency in a frequency component of the heart sounds within the target range, and a second processing portion configured to output a detection signal indicating that there is a high probability of severe aortic stenosis in a case where the peak frequency is a peak reference value or greater.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
To provide a collagen sponge excellent in mechanical strength and a production method for the collagen sponge. A collagen sponge including a porous construct having a pore structure, the collagen sponge having a tensile strength of 1 N or more and 5 N or less in every direction including a length direction and a width direction. The collagen sponge may be produced by a production method including the following steps: (1) a step of subjecting a collagen solution obtained by mixing collagen and a solvent to stirring and deaeration treatment; (2) a step of subjecting the collagen solution to freeze-dry treatment; and (3) a step of subjecting a dried collagen product after the freeze-dry treatment to insoluble treatment.
C08J 9/28 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolaires; Leur post-traitement par élimination d'une phase liquide d'un objet ou d'une composition macromoléculaire, p.ex. par séchage du coagulum
35.
SEMICONDUCTOR NANOPARTICLES AND METHOD OF PRODUCING SEMICONDUCTOR NANOPARTICLES
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
NICHIA CORPORATION (Japon)
Inventeur(s)
Kuwabata, Susumu
Uematsu, Taro
Wajima, Kazutaka
Torimoto, Tsukasa
Kameyama, Tatsuya
Oyamatsu, Daisuke
Niki, Kenta
Abrégé
A semiconductor nanoparticle includes a core and a shell covering a surface of the core. The shell has a larger bandgap energy than the core and is in heterojunction with the core. The semiconductor nanoparticle emits light when irradiated with light. The core is made of a semiconductor that contains M1, M2, and Z. M1 is at least one element selected from the group consisting of Ag, Cu, and Au. M2 is at least one element selected from the group consisting of Al, Ga, In and Tl. Z is at least one element selected from the group consisting of S, Se, and Te. The shell is made of a semiconductor that consists essentially of a Group 13 element and a Group 16 element.
C09K 11/62 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du gallium, de l'indium ou du thalium
B01J 13/02 - Fabrication de microcapsules ou de microbilles
C09K 11/02 - Emploi de substances particulières comme liants, revêtements de particules ou milieux de suspension
C09B 67/02 - Préparations tinctoriales caractérisées par un aspect physique particulier, p.ex. tablettes, feuilles
According to one embodiment, a liquid crystal optical element includes a first liquid crystal layer including a first cholesteric liquid crystal and a second liquid crystal layer including a second cholesteric liquid crystal, a helical pitch of each of the first cholesteric liquid crystal and the second cholesteric liquid crystal changing continuously. The first cholesteric liquid crystal including a first portion having a first helical pitch and a second portion having a second helical pitch different from the first helical pitch. The second cholesteric liquid crystal including a third portion having a third helical pitch and a fourth portion having a fourth helical pitch different from the third helical pitch.
Kyoto Prefectural Public University Corporation (Japon)
Inventeur(s)
Matsusaki, Michiya
Louis, Fiona
Kitano, Shiro
Sowa, Yoshihiro
Abrégé
The present invention relates to a method for freezing a cell structure including freezing a cell structure including fragmented extracellular matrix components, cells and fibrin and having a three-dimensional tissue structure.
A joint evaluation apparatus includes an inertial sensor unit that is attached in a vicinity of a joint with joint axes of the joint to connect bones on both sides parallel to a detection axis and detects motion of a bone of a joint axis of which a range of motion of joint movement is limited, among the joint axes, as a waveform signal, a load detection unit that detects a load applied to the joint, a data obtaining unit that, when detecting generation of the load, obtains the waveform signal to be detected by the inertial sensor unit, in a time direction and an intensity direction, and a feature amount calculation unit that analyzes the waveform signal and calculates a feature amount that evaluates movement quality of the joint.
[Problem] The present invention addresses the problem of providing a muscle function-improving agent for suppressing or improving the decline of muscular functions due to aging. [Solution] Provided is a muscle function-improving agent for suppressing or improving the functional decline of skeletal muscle due to aging, the muscle function-improving agent containing, as an active ingredient, at least one peptide selected from among the following (1)-(3), or a salt thereof: (1) a peptide consisting of the amino acid sequence represented by SEC) ID NO: 1; (2) a peptide which is the fragment of human osteopontin, and in which the C-terminal amino acid sequence is the amino acid sequence represented by SEQ ID NO: 1; and (3) a peptide which consists of an amino acid sequence obtained by substituting, adding, or deleting one or more amino acids in the amino acid sequence of the peptide in (1) or (2), and has the action of suppressing or ameliorating the functional decline of skeletal muscle due to aging.
Provided are preventive or therapeutic agents for fibrotic diseases and cancer. A Wnt signaling pathway inhibitor or a preventive and therapeutic agent for fibrotic diseases or cancer, both comprising an oligopeptide consisting of an amino acid sequence containing a DE loop sequence of RANKL protein and a β-strand sequence of RANKL protein placed adjacent to the N-terminal side of the DE loop sequence.
The present invention provides human cells that can be stably infected with coronavirus, as human cells for research on infection with coronavirus such as SARS-CoV-2, as well as, by utilizing the cells, a method for confirming the presence of a coronavirus in a sample, a method for producing a coronavirus, and a method for evaluating the presence or absence of anti-coronavirus activity of a test sample or a substance having an anti-coronavirus neutralizing action in a test sample. Specifically, the present invention relates to a method for preparing a coronavirus-infectious immortalized human myeloid cell, including introducing ACE2 and TMPRSS2 into an immortalized human myeloid cell, and the like.
C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p.ex. thromboplastine, aminopeptidase de la leucine (3.4)
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
According to one embodiment, a liquid crystal optical element includes a transparent substrate including a main surface, an alignment film disposed on the main surface, and a liquid crystal layer overlapping the alignment film and including a cholesteric liquid crystal including liquid crystal molecules stacked helically and an additive exhibiting a liquid crystalline property. In the liquid crystal layer, a reflective surface along which alignment directions of the liquid crystal molecules are identical is inclined with respect to the main surface.
Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The objective of the present invention is to provide a friction pressure welding method with which the welding temperature can be controlled accurately, the welding temperature can be lowered, and the distribution of the welding temperature at an interface to be welded can be made uniform; and to provide a welded structure obtained by this method. The present invention relates to the friction pressure welding method in which one member is abutted against another member and is made to slide in a state in which a welding pressure substantially perpendicular to the interface to be welded is applied, said friction pressure welding method being characterized in that the maximum sliding speed is no greater than 53 mm/sec, the difference in the temperature increase rate between a center portion and an outer peripheral portion at the interface to be welded is 10° C./sec or less, and the difference between the maximum attained temperature between the center portion and the outer peripheral portion at the interface to be welded is no greater than 50° C.
B23K 20/12 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p.ex. revêtement ou placage la chaleur étant produite par friction; Soudage par friction
Japan Represented by Director General of National Institute of Health Sciences (Japon)
Inventeur(s)
Obika, Satoshi
Yamaguchi, Takao
Komine, Hibiki
Sugiura, Takaya
Inoue, Takao
Yoshida, Tokuyuki
Abrégé
Disclosed are a bridged nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The bridged nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The bridged nucleoside also has excellent industrial productivity.
Disclosed are a bridged nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The bridged nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The bridged nucleoside also has excellent industrial productivity.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
A solar cell device (100) includes an optical waveguide section (1), a solar cell (5), and a light diffracting section (3). The light diffracting section (3) is disposed in a different layer level from the optical waveguide section (1) and is opposite to the optical waveguide section (1). The light diffracting section (3) diffracts light (LT2) in at least a portion of a wavelength band of light (LT1) incident to the light diffracting section (3) toward the optical waveguide section (1) and allows the light (LT2) in at least the portion of the wavelength band to enter the optical waveguide section (1). The optical waveguide section (1) guides the light (LT2) diffracted by the light diffracting section (3) and entering inside the optical waveguide section (1). The solar cell (5) receives the light (LT2) guided by the optical waveguide section (1) and converts energy of the light (LT2) to electrical power.
H01L 31/054 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails adaptés comme dispositifs de conversion photovoltaïque [PV] Éléments optiques directement associés ou intégrés à la cellule PV, p.ex. moyens réflecteurs ou concentrateurs de lumière
47.
WELD INSPECTION DEVICE, WELDING SYSTEM, AND WELD INSPECTION METHOD
A generation laser irradiation device irradiates a weld after welding with a generation laser. A detection laser probe irradiates an ultrasonic detection point that passes through the weld and is capable of detecting an ultrasonic wave reflected on a lower surface of a base material with detection laser. A control device determines existence of an internal defect of the weld based on a measurement result of a laser interferometer. The generation laser irradiation device includes a scanning mechanism that scans an irradiation position of the generation laser in a direction intersecting a welding direction.
B23K 31/12 - Procédés relevant de la présente sous-classe, spécialement adaptés à des objets ou des buts particuliers, mais non couverts par un seul des groupes principaux relatifs à la recherche des propriétés, p.ex. de soudabilité, des matériaux
B23K 9/095 - Surveillance ou commande automatique des paramètres de soudage
Provided is DNA that: encodes a coronavirus (SARS CoV-2) spike protein or a fragment thereof; and has been optimized to partially or fully exhibit a codon included in a DNA sequence.
The invention relates to a method of producing the radiolabeled aryl compound (I) Ar—X, or a salt thereof, wherein X is 211At, 210At, 123I, 124I, 125I, or 131I. The method involves reacting the aryl boronic acid compound (II) Ar—Y, or a salt thereof, wherein Y is a borono group (—B(OH)2) or an ester group thereof, with a radionuclide selected from 211At, 210At, 123I, 124I, 125I and 131I, in the presence of an oxidizing agent selected from an alkali metal iodide, an alkali metal bromide, N-bromosuccinimide, N-chlorosuccinimide and hydrogen peroxide, in water.
The present invention provides a graphene grid that can suppress or prevent uneven distribution, uneven orientation, and the like of a structural analysis target substance, and can capture the structural analysis target substance with high efficiency and analyze the structural analysis target substance with high resolution, in a structural analysis by cryo-electron microscopy. A graphene grid of the present invention has a graphene surface into which a functional group is introduced.
The present invention relates to a method for producing a three-dimensional tissue body, including: a step of obtaining a mixture by mixing a cationic substance and a fragmented extracellular matrix component with cells; and a step of culturing the cells after the step of obtaining the mixture.
The present invention provides a medicament for treating cancer comprising, as an active ingredient, an apolipoprotein and/or interferon regulatory factor 7 (IRF7), wherein the expression of the apolipoprotein and IRF7 is increased in cancer cells by treatment of the cancer cells with hemagglutinating virus of Japan-envelope (HVJ-E); the medicament for treating cancer used in combination with a T-cell co-stimulator agonist; and an immunostimulant comprising a combination of a T-cell co-stimulator agonist and at least one selected from the group consisting of an apolipoprotein, IRF7 and HVJ-E.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
By administering a liposome formulation in which an antibacterial agent is bound to a liposome, in particular, a lipid-soluble side chain of the antibacterial agent is bound to a lipid of the liposome, and the antibacterial agent extends outward from a surface of the liposome, it is possible to provide a liposome formulation in which blood retention of an active ingredient is increased, an amount of the active ingredient taken by a reticuloendothelial system such as a liver is reduced, an amount of the active ingredient transferred into a kidney is reduced, and antibacterial activity can also be increased with little resistance.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
The present invention provides an immunogenic composition comprising an antigenic peptide and a carrier protein, wherein the antigenic peptide is capable of eliciting production of an antibody against a phosphorylated tau protein and is a human tau protein fragment containing (1) YSpSPGpSPG (SEQ ID NO: 2), (2) AKpSpTPpTAE (SEQ ID NO: 5), (3) AKpSpTPTAE (SEQ ID NO: 31), (4) AKpSTPpTAE (SEQ ID NO: 32), (5) AKSpTPpTAE (SEQ ID NO: 33), or (6) IVpYKpSPV (SEQ ID NO: 24).
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The invention provides a method for producing a solution containing 211At− (astatide ion) at a high radiochemical purity by using 211At obtained by a nuclear reaction as a starting material, including a step of adding a reducing agent to a solution containing an impurity derived from 211At. The invention also provides a solution containing 211At− (astatide ion) at a radiochemical purity of not less than 30%.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p.ex. émulsion, microcapsules, liposomes
A medical diagnostic apparatus includes a receiver circuit that receives three-dimensional volumetric data of a subject’s eye, and a processor configured to separate portions of the three-dimensional volumetric data into separate segments, perform processing differently on each of the separate segments, and combine the separately processed segments to produce an enhanced three-dimensional volumetric data set. The processor is further configured to generate at least one diagnostic metric from the enhanced three-dimensional volumetric data set, and the processor is further configured to evaluate a pathological condition based on the at least one diagnostic metric. Related methods and computer readable media are also disclosed.
G06T 7/30 - Détermination des paramètres de transformation pour l'alignement des images, c. à d. recalage des images
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 3/12 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p.ex. ophtalmoscopes
An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A flexible ultrasonic wave generating device (2) is inserted into a flexible tube (10) having flexibility, and an inductor (15), a discharge resistor (21), an FET (22), and an SBD (23) constituting a drive circuit (25) are mounted on first to third flexible substrates (11) to (13). An actuator (14) is connected to the distal end portion of the flexible ultrasonic wave generating device (2). An active blade (30) is attached to the actuator (14).
A data converting device includes a processor that executes a procedure. The procedure includes: for each of plural conversion rules, specifying a difference between pre-conversion data and post-conversion data generated by applying the plural conversion rules respectively to the pre-conversion data; determining application probabilities of the plural conversion rules respectively, in accordance with deviations in first plural data based on a first attribute of the first plural data and the differences for the plurality conversion rules; and generating second plural data by applying the plural conversion rules to the first plural data based on the application probabilities.
Any one or both of an optical system with a structured lighting pattern and a structured detecting system having a plurality of regions with different optical characteristics are used. In addition, optical signals from an object to be observed through one or a small number of pixel detectors are detected while changing relative positions between the object to be observed and any one of the optical system and the detecting system, time series signal information of the optical signals are obtained, and an image associated with an object to be observed from the time series signal information is reconstructed.
The present invention aims to provide a prophylactic and/or therapeutic agent for diabetes that is highly effective on diabetes developed as a side effect from immune checkpoint inhibitors and has a certain effect on many patients. The present invention is a therapeutic agent for diabetes comprising mesenchymal stem cells. The prophylactic and/or therapeutic agents for diabetes of the present invention are suitably used particularly for diabetes caused by immune checkpoint inhibitors and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.
A data generation device according to the present invention is a data generation device configured to simulatively generate data used when creating, by machine learning, a discriminator configured to detect a peak observed in a signal waveform, the data generation device including: a parameter frequency information acquisition unit configured to acquire information on frequency of a predetermined shape parameter which characterizes a shape of a signal waveform from a plurality of signal waveforms collected only in a target field of machine learning for creating the discriminator; and a simulated waveform generation unit configured to generate a simulated signal waveform which is able to include overlapping of a plurality of peaks and noise using the information on frequency of the shape parameter, in which the simulated signal waveform is provided as data for training or evaluating machine learning.
A water- and oil-repellent composition including a copolymer having a repeating unit derived from a hydrophobic monomer having an ethylenically unsaturated double bond and a hydrocarbon group having from 3 to 40 carbon atoms, and a repeating unit that is derived from a cyclic vinylidene monomer, which is a compound represented by formula (wherein X represents an aliphatic group having from 1 to 10 carbon atoms; and Z represents at least one atom or group that is selected from a hydrogen atom, a hydrocarbon group having from 1 to 6 carbon atoms, and halogen atoms). Also disclosed is method for producing the water- and oil-repellent composition; as well as a textile product to which the copolymer in the water- and oil-repellent composition is attached.
C08F 224/00 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par un hétérocycle contenant de l'oxygène
C09D 137/00 - Compositions de revêtement à base d'homopolymères ou de copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, chacun ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par un hétéroc; Compositions de revêtement à base de dérivés de tels polymères
64.
ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE
In order to provide an organic compound that can be suitably used as a luminescent material for a display, and an organic light emitting device containing such an organic compound, an organic compound in accordance with an embodiment of the present invention has a lone electron-pair and a π E electron orbit, and in the organic compound, an energy gap ΔEST obtained by subtracting an energy level ET1 of a lowest triplet excitation state T1 from an energy level ES1 of a lowest singlet excitation mode S1 is −0.20 eV≤ΔEST<0.0090 eV.
The present invention provides an oral care agent suitable for removing oral deposits. An oral care agent of the present invention is a semi-solid oral care agent that is an agent for removing oral deposits.
A terahertz module includes: a terahertz chip which includes an active device which emits a terahertz wave; and a dielectric substrate coupled to the terahertz chip. The terahertz chip includes a semiconductor substrate. The active device is disposed on an upper surface of the semiconductor substrate. A cutout is formed in a portion of a first side surface, among a plurality of side surfaces of the dielectric substrate, the cutout extending from an upper side of the first side surface to a lower side of the first side surface. The terahertz chip is fit into the cutout in such a direction that the upper surface of the semiconductor substrate is parallel to the first side surface and the semiconductor substrate is arranged in a bottom side of the cutout.
H01L 23/538 - Dispositions pour conduire le courant électrique à l'intérieur du dispositif pendant son fonctionnement, d'un composant à un autre la structure d'interconnexion entre une pluralité de puces semi-conductrices se trouvant au-dessus ou à l'intérieur de substrats isolants
H01L 21/768 - Fixation d'interconnexions servant à conduire le courant entre des composants distincts à l'intérieur du dispositif
H01L 29/66 - Types de dispositifs semi-conducteurs
H01P 3/16 - Guides d'ondes diélectriques, c. à d. sans conducteur longitudinal
According to one embodiment, a liquid crystal optical element includes a substrate, a first alignment film, a second alignment film opposite to the first alignment film, a spacer between the substrate and the second alignment film, and a liquid crystal layer in contact with the first alignment film and the second alignment film. The liquid crystal layer includes liquid crystal molecules including a plurality of first liquid crystal molecules arranged along a boundary surface with the first alignment film and a plurality of second liquid crystal molecules arranged along a boundary surface with the second alignment film, and is cured in a state where alignment directions of the liquid crystal molecules are fixed.
According to one embodiment, a photovoltaic cell device includes an optical waveguide including a first main surface, a second main surface opposed to the first main surface, and a side surface, an optical element opposed to the second main surface, containing cholesteric liquid crystal, and reflecting at least a part of incident light via the optical waveguide toward the optical waveguide, a photovoltaic cell opposed to the side surface, and a protective film, and the protective film is provided to be in contact with the first main surface.
H01L 31/054 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails adaptés comme dispositifs de conversion photovoltaïque [PV] Éléments optiques directement associés ou intégrés à la cellule PV, p.ex. moyens réflecteurs ou concentrateurs de lumière
According to one embodiment, a nitride crystal includes first, second, and third nitride crystal regions. The third nitride crystal region includes Al, and is provided between the first and second nitride crystal regions. A third oxygen concentration in the third nitride crystal region is greater than a first oxygen concentration in the first nitride crystal region and greater than a second oxygen concentration in the second nitride crystal region. A third carbon concentration in the third nitride crystal region is greater than a first carbon concentration in the first nitride crystal region and greater than a second carbon concentration in the second nitride crystal region. A <0001> direction of the first nitride crystal region is one of a first orientation from the second nitride crystal region toward the first nitride crystal region or a second orientation from the first nitride crystal region toward the second nitride crystal region.
H01L 29/20 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des composés AIIIBV
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
C23C 16/30 - Dépôt de composés, de mélanges ou de solutions solides, p.ex. borures, carbures, nitrures
G02F 1/355 - Optique non linéaire caractérisée par les matériaux utilisés
G02F 1/37 - Optique non linéaire pour la génération de l'harmonique deux
70.
SEMICONDUCTOR NANOPARTICLES, METHOD OF PRODUCING THE SEMICONDUCTOR NANOPARTICLES, AND LIGHT-EMITTING DEVICE
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
OSAKA UNIVERSITY (Japon)
NICHIA CORPORATION (Japon)
Inventeur(s)
Torimoto, Tsukasa
Kameyama, Tatsuya
Kishi, Marino
Miyamae, Chie
Kuwabata, Susumu
Uematsu, Taro
Oyamatsu, Daisuke
Niki, Kenta
Abrégé
Semiconductor nanoparticles including Ag, In, Ga, and S are provided. In the semiconductor nanoparticles, a ratio of a number of Ga atoms to a total number of In and Ga atoms is 0.95 or less. The semiconductor nanoparticles emit light having an emission peak with a wavelength in a range of from 500 nm to less than 590 nm, and a half bandwidth of 70 nm or less, and have an average particle diameter of 10 nm or less.
H01L 33/50 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les éléments du boîtier des corps semi-conducteurs Éléments de conversion de la longueur d'onde
C09K 11/62 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du gallium, de l'indium ou du thalium
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
H01L 33/06 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure à effet quantique ou un superréseau, p.ex. jonction tunnel au sein de la région électroluminescente, p.ex. structure de confinement quantique ou barrière tunnel
71.
METHOD AND APPARATUS FOR DETECTING OCULAR MOVEMENT DISORDERS
A system for identifying abnormal eye movements includes a near-eye display (NED), an eye-tracking camera, a frame supporting the NED and the eye-tracking camera, and a processor in data communication with the NED, the eye-tracking camera, and a computer readable medium. The computer readable medium has instructions thereon. When executed by the processor, the instructions cause the processor to provide a target on the NED to a user's eye and change the target or move the target to a plurality of locations in three dimensions on the NED according to one or more tasks of a task module. The processor further records positional information and pupil information of the user's eye during the one or more tasks of the task module and compares the positional information to at least one threshold value of an abnormality identification algorithm.
A61B 3/113 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
A61B 3/11 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la distance interpupillaire ou le diamètre de la pupille
A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 3/00 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux
72.
MAGNETIC GEAR, ACTUATOR UNIT HAVING THE SAME, AND LINK MECHANISM USING THE SAME
Provided is a magnetic gear which has a large transmission torque, stability, and a simple structure. A magnetic gear (30) includes: a first magnetic pole array (34) that includes first N poles (35) and first S poles (36) alternately arranged on an outer peripheral inclined surface (32) of a rotary disc (31); a second magnetic pole array (37) that includes second N poles (38) and second S poles (39) alternately arranged on the outer peripheral inclined surface (32), one of the second N poles (38) is positioned at a location corresponding to an intermediate position between a corresponding one of the first N poles (35) and a corresponding one of the second S poles (36) that are adjacent to each other.
B25J 9/10 - Manipulateurs à commande programmée caractérisés par des moyens pour régler la position des éléments manipulateurs
73.
ACQUISITION METHOD OF VALUE RELATING TO TRIGLYCERIDE METABOLIC CAPACITY, PRESENTATION METHOD OF DISEASE INFORMATION, PRESENTATION METHOD OF DISEASE DIFFERENTIATION INFORMATION, PRESENTATION METHOD OF THERAPY EFFICACY INFORMATION, PRESENTATION METHOD OF THERAPEUTIC EFFECT INFORMATION, TEST REAGENT AND TEST KIT
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
Inventeur(s)
Hirano, Ken-Ichi
Hara, Yasuhiro
Kashiwagi, Hirokazu
Suzuki, Akira
Jin, Takashi
Monde, Kenji
Murai, Yuta
Abrégé
Provided are a method for acquiring a value relating to a triglyceride metabolic capacity of a subject within a shorter period of time compared to conventional nuclear medicine methods, and a test reagent and a test kit that are to be used in the acquisition method. This problem can be solved by an acquisition method of a value relating to the triglyceride metabolic capacity in leucocytes of a subject, said method comprising: a first step of mixing, in vitro, a fatty acid compound labeled with a fluorescent substance with leucocytes collected from the subject and thus bringing the fatty acid labeled with the fluorescent substance into contact with the leucocytes, wherein the fatty acid compound contains a fatty acid residue, the fatty acid residue has 8-26 carbon atoms, and a part of hydrogen atoms constituting the fatty acid residue, excluding a terminal methyl group of the fatty acid residue, may be substituted by an alkyl group having 1-3 carbon atoms; and a second step of acquiring, as the value relating to the triglyceride metabolic capacity, a measured fluorescence intensity that is derived from the fluorescent label in the leucocytes.
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
C07C 229/34 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
A method of treating bradyarrhythmia includes administering to a patient having bradyarrhythmia a therapeutically effective amount of at least one of compound (I) and compound (II) or pharmacologically acceptable salts thereof as an active component:
A method of treating bradyarrhythmia includes administering to a patient having bradyarrhythmia a therapeutically effective amount of at least one of compound (I) and compound (II) or pharmacologically acceptable salts thereof as an active component:
A method of treating bradyarrhythmia includes administering to a patient having bradyarrhythmia a therapeutically effective amount of at least one of compound (I) and compound (II) or pharmacologically acceptable salts thereof as an active component:
wherein Ph is a phenyl group.
A61K 31/4741 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. dérivés du tubocurarane, noscapine, bicuculline
According to one embodiment, a solar power generation apparatus includes an optical waveguide that includes a first main surface, a second main surface, and a lower side surface, an optical element that faces the second main surface, includes cholesteric liquid crystal, and reflects at least a part of ultraviolet ray of incident light from the first main surface toward the optical waveguide, and a solar cell that faces the lower side surface. The optical element includes a reflective surface angled with respect to a boundary surface between the optical waveguide and the optical element. An inclination angle of the reflective surface with respect to the boundary surface is an acute angle toward the solar cell.
An adenocarcinoma detection method based on a protein fragment of WFDC2 protein in a sample originating from a subject, the method comprising determining a presence of adenocarcinoma by comparing a first determination value and a threshold value set in advance, the first determination value being a value derived by dividing a first fragment quantity, which is a quantity of a protein fragment having an amino acid sequence of SEQ ID NO: 1 in the sample as determined by an ELISA method, by a reference quantity defined by a total quantity of WFDC2 protein or a creatinine concentration in the sample as determined by an ELISA method.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
G01N 33/70 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir la créatine ou la créatinine
77.
Peptide Having Mesenchymal Stem Cell Mobilizing Activity
The present inventors synthesized a plurality of peptides each consisting of a partial sequence of the artificial sequence peptide “1r10” (1r10 fragment peptides), which was discovered from their own research conducted to date, investigated whether they have an activity of mobilizing mesenchymal stem cells into peripheral blood, and as a result, discovered that a 1r10 fragment peptide having a specific amino acid sequence shows the activity. Based on such finding, a peptide is provided which is considered to show therapeutic effects on various diseases through mobilization of mesenchymal stem cells into peripheral blood.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
78.
THERAPEUTIC AGENT FOR DRUG-INDUCED BRADYCARDIA AND BRADYARRHYTHMIA
A therapeutic agent for drug-induced bradycardia and bradyarrhythmia. A therapeutic agent for drug-induced bradycardia and bradyarrhythmia including, as an active ingredient, the following compound (I):
A therapeutic agent for drug-induced bradycardia and bradyarrhythmia. A therapeutic agent for drug-induced bradycardia and bradyarrhythmia including, as an active ingredient, the following compound (I):
A therapeutic agent for drug-induced bradycardia and bradyarrhythmia. A therapeutic agent for drug-induced bradycardia and bradyarrhythmia including, as an active ingredient, the following compound (I):
(wherein Ph is a phenyl group) or a pharmacologically acceptable salt of the compound.
A61K 31/4741 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. dérivés du tubocurarane, noscapine, bicuculline
An analysis device includes an analysis unit configured to receive scattered light, transmitted light, fluorescence, or electromagnetic waves from an observed object located in a light irradiation region light-irradiated from a light source and analyze the observed object on the basis of a signal extracted on the basis of a time axis of an electrical signal output from a light-receiving unit configured to convert the received light or electromagnetic waves into the electrical signal.
G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G01N 15/14 - Recherche par des moyens électro-optiques
G01N 21/27 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
G06F 18/28 - Détermination de motifs de référence représentatifs, p.ex. en faisant la moyenne ou en déformant; Génération de dictionnaires
G06F 18/21 - Conception ou mise en place de systèmes ou de techniques; Extraction de caractéristiques dans l'espace des caractéristiques; Séparation aveugle de sources
G06V 10/772 - Détermination de motifs de référence représentatifs, p.ex. motifs de valeurs moyennes ou déformants; Génération de dictionnaires
G06V 10/778 - Apprentissage de profils actif, p.ex. apprentissage en ligne des caractéristiques d’images ou de vidéos
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
The present invention relates to a gold nanoparticle-containing medicine, and a treatment of a proliferative disease using the medicine. The present invention also relates to a gold nanoparticle-containing medicine that is bound to an alpha radioactive nucleus, and a treatment of a proliferative disease using the medicine.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p.ex. enzymes pancréatiques
81.
FORECASTING APPARATUS, FORECASTING METHOD, AND STORAGE MEDIUM
A forecasting apparatus forecasts an event after a predetermined time, based on a current window being a part of time-series data in multidimension. The forecasting apparatus includes a non-linear transformation unit including a matrix for non-linear transformation, an observation matrix, and a seasonality setting unit. The non-linear transformation unit transforms the time-series data of the current window in a part of dimensions that are related to trends and the time-series data of the current window in a part of dimensions that are related to seasonal intensity into latent first data showing the trends and latent second data showing the seasonal intensity. The observation matrix includes a first observation matrix that reproduces the first data to first estimated data of an original number of dimensions, and a second observation matrix that, by use of seasonality information that has been set in the seasonality setting unit, reproduces the second data to second estimated data of an original number of dimensions, and adds the first estimated data and the second estimated data.
G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
The derivation unit determines the stability of a parasympathetic nerve activity of the sleeper for each environment temperature, and derives a correspondence relationship between the environment temperature and the stability of the parasympathetic nerve activity of the sleeper. An estimation unit estimates an appropriate value of the environment temperature suitable for the sleeper based on the correspondence relationship derived by the derivation unit.
Provided is a system for estimating a subjective evaluation by an estimation subject. This system for estimating a subjective evaluation by an estimation subject comprises: a reception means that receives feature data of a biosignal acquired from the estimation subject; a storage means that stores a plurality of feature templates extracted from a plurality of biosignals acquired from a plurality of subjects to be modeled including a first subject to be modeled and a second subject to be modeled, or that stores a plurality of models trained using said feature templates; and an estimation means that estimates a subjective evaluation by the estimation subject on the basis of the feature data and the plurality of feature templates or the plurality of models.
An object of the present invention is to provide a method of assisting diagnosis of inflammatory bowel disease, which can specifically determine inflammatory bowel disease.
An object of the present invention is to provide a method of assisting diagnosis of inflammatory bowel disease, which can specifically determine inflammatory bowel disease.
The present invention relates to “a method of assisting diagnosis of inflammatory bowel disease, the method including subjecting a subject-derived specimen to a reduction treatment and subsequently measuring a human prohaptoglobin amount in the specimen by using an antibody 1 which is an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO: 1, and determining that a subject has inflammatory bowel disease by using the human prohaptoglobin amount as an indicator, and relates to an examination kit for assisting diagnosis of inflammatory bowel disease, including the antibody 1 a reducing agent”.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A multi-component system alloy includes titanium, zirconium, niobium, molybdenum, and tantalum, and further the multi-component system alloy includes at least one selected from the group consisting of hafnium, tungsten, vanadium, and chromium, wherein the alloy satisfies Mo equivalent ≧ 13.5, and the alloy is a single-phase solid solution, a two-phase solid solution, or an alloy in which a main phase is a solid solution phase.
A measuring device facilitates equipment calibration. A measuring device for measuring noise contained in equipment having a prescribed resistance value is provided with a first voltage-dividing circuit connected to a direct-current power source, a second voltage-dividing circuit connected in parallel with the first voltage-dividing circuit , and a measuring unit which measures a first voltage-divided voltage output from the first voltage-dividing circuit, and a second voltage-divided voltage output from the second voltage-dividing circuit, a calculating unit which calculates the difference between the measured first voltage-divided voltage and second voltage-divided voltage, and an output unit which outputs the calculated result, wherein: the first voltage-dividing circuit outputs the first voltage-divided voltage from the equipment and a first resistor, connected in series.
The present invention provides an agent for inducing regression of triglyceride (TG) deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, an agent for improving blood flow in a patient with TG deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, and a pharmaceutical or food or drink product comprising the agent for inducing regression of TG deposit atherosclerosis or the agent for improving blood flow.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
An actuator unit (1) includes a direct drive motor (2), a first magnetic gear (3) connected to a rotating shaft (6) of the direct drive motor (2), a second magnetic gear (4) configured to be magnetically engaged with the first magnetic gear (3), and a planetary reducer (5) connected to a rotating shaft of the second magnetic gear (4).
(Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFRα-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body.
(Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFRα-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body.
(Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFRα-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFRα-positive cells.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
91.
BRAIN IMAGE ANALYSIS APPARATUS, CONTROL METHOD, AND COMPUTER READABLE MEDIUM
A brain image analysis apparatus (2000) acquires input data (40) including a structural brain image (42) and a functional brain image (44) for a subject (10). The brain image analysis apparatus (2000) obtains analysis data (20) by inputting the input data (40) into an analysis model (2020). The analysis model (2020) has been trained in advance so as to output the analysis data (20) representing information about brain dysfunction in response to an input of the input data (40). The brain image analysis apparatus (2000) outputs, based on the analysis data (20), output data (30) representing information about the brain dysfunction of the subject (10).
An optical signal detection system includes: a nonlinear converter that nonlinearly converts a plurality of first optical signals into a plurality of second optical signals, and also a third optical signal into a fourth optical signal; a spectrometer that obtains each of a plurality of first spectral data items from a different one of the plurality of second optical signals, and also a third spectral data item from the fourth optical signal; and a detection device that detects the third optical signal and outputs a detection result. The detection device includes: an analyzer that performs sparse principal component analysis on the plurality of first spectral data items to generate a plurality of second spectral data items; and a detector that compares the third spectral data item with each of the plurality of second spectral data items, and detects the third optical signal based on the result of the comparison.
A magnetic body inspection method and magnetic body inspection apparatus (1) that has a magnet (10) and a magnetic sensor (20) that outputs electric signals. At least two electric signals are obtained by the magnetic sensor (20). A magnetic body present inside a nonmagnetic body can be detected non-destructively, by outputting the difference between the two obtained electric signals.
G01N 27/82 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables magnétiques pour rechercher la présence des criques
G01R 33/07 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs galvano-magnétiques des dispositifs à effet Hall
G01R 33/00 - Dispositions ou appareils pour la mesure des grandeurs magnétiques
94.
Electromagnetic wave determining device, flow cytometer, electromagnetic wave determining method, and electromagnetic wave determining program
An electromagnetic wave detecting device comprising: an emission unit configured to emit electromagnetic waves having coherence; an electromagnetic wave modulating unit configured to modulate one or both of a phase and an amplitude of the emitted electromagnetic waves and to change a state of the modulation relative to an imaging target; and a post-modulation electromagnetic wave intensity detecting unit configured to detect an intensity of post-modulation electromagnetic waves, which are the modulated electromagnetic waves acquired by modulating the electromagnetic waves emitted from the emission unit using the imaging target and the electromagnetic wave modulating unit, using one pixel.
An object is to provide a catheter and a branched connector that can improve sealing properties and have high versatility. In a branched connector 40 used in a catheter 100, the branched connector 40 comprises a first end portion 44 to which a catheter main body 10 is attached and having a first hole portion 43 communicating with the catheter main body 10 being formed at the first end portion 44, and a second end portion 49 including an elastic member and having a second hole portion 48 for inserting a wire-like instrument 20 being formed in the elastic member, and the second hole portion 48 communicates with the first hole portion 43 and has a flow passage area smaller than a flow passage area of the first hole portion 43.
A glass powder composite includes a first glass powder, and a second glass powder having a different solubility from that of the first glass powder depending on pH, wherein both the first glass powder and the second glass powder have ion sustained-release properties.
The present invention provides a gel formed of fibrin and a molecule generated by thrombin treatment of a chimeric protein that comprises a fibrinogen fragment capable of binding to fibrinogen upon thrombin treatment and a laminin fragment having integrin-binding activity, and optionally further comprises a protein having growth factor-binding activity. The gel of the present invention is suitable as a gel substrate that has properties of the basement membrane and can be used in medical applications.
C07K 14/78 - Peptides du tissu connectif, p.ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid (CIG)
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
98.
GEL COMPOSITION AND PRODUCTION METHOD THEREFOR, AND THREE-DIMENSIONAL TISSUE BODY AND PRODUCTION METHOD THEREFOR
The present invention relates to a gel composition containing at least one selected from the group consisting of an extracellular matrix component and a fragmented extracellular matrix component, and an ion of a metal element.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
The present disclosure provides a method for analyzing a microRNA using a tunneling current. The present disclosure provides a method for identifying the base sequence and/or modification state of a microRNA using a tunneling current, and a system and a program to be used in the method. Furthermore, the present disclosure provides a method for analyzing the conditions of a subject, said method comprising determining the base sequence and/or modification state of a microRNA using a tunneling current. For example, methylation modification can be analyzed thereby.
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p.ex. l'émission cathodique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
100.
HOST-GROUP-CONTAINING POLYMERIZABLE MONOMER, POLYMER MATERIAL, METHOD FOR PRODUCING SAME, AND CLATHRATE COMPOUND AND METHOD FOR PRODUCING SAME
Provided are a host-group-containing polymerizable monomer usable as a starting material for producing a macromolecular material with a high degree of freedom in material design, and excellent toughness and strength; a macromolecular material produced using the host-group-containing polymerizable monomer; and a method for producing the macromolecular material. The host-group-containing polymerizable monomer according to the present invention is a host-group-containing polymerizable monomer, and the host group is a monovalent group formed by removing one hydrogen atom or hydroxy group from a cyclodextrin derivative. The cyclodextrin derivative has such a structure that the hydrogen atom of at least one hydroxy group of a cyclodextrin is replaced with a group selected from the group consisting of a hydrocarbon group, an acyl group, and —CONHR wherein R represents a methyl group or an ethyl group.
brevets
